Ascendis Pharma A/S ASND
Set alert
249.66 USD +0.68 +0.27%
As of Nov 3, 11:40 AM ET
248.57 Day range 252.75
188.07 52-week range 282.15
- YTD
- +17.08%
- 1 year
- +24.22%
- Open
- 248.57
- Prev close
- 248.98
- Mkt cap
- 16.41B
- Vol
- 105.61K
- Avg vol
- 700.84K
- EPS
- 13.05
- P/E
- 19.11
- Div yield
- 0.00%
More statistics
- Low
- 248.57
- High
- 252.75
- Forward P/E
- 24.90
- Beta
- 0.00
- Short ratio
- 3.27
- Inst. own
- 103.67%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 242.31
- 200-d avg
- 238.10
- 1y target
- 304.67
5Y chart
Events in this range
- Aug 7, 2025Earnings: -0.93; estimate -1.42; surprise 34.51%
- Nov 12, 2025Earnings: -1.17; estimate -0.41; surprise -185.37%
- Feb 11, 2026Earnings: -0.64; estimate -0.06; surprise -966.67%
- May 7, 2026Earnings: 0.32; estimate 0.1876; surprise 70.58%
- Aug 13, 2026Earnings: 3.29; estimate 1.71; surprise 92.4%
- Sep 1, 2026Rating: Wedbush · Outperform → Outperform
- Sep 1, 2026Rating: Morgan Stanley · Overweight → Overweight
- Sep 2, 2026Rating: Oppenheimer · Outperform → Outperform
- Sep 15, 2026Downgrade: Raymond James · Strong Buy → Outperform
- Sep 25, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Oct 26, 2026Rating: Citigroup · Buy → Buy
Signals (125)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 25, 2026 | 5 months ago |
| MACD: Sell Signal | May 25, 2026 | 5 months ago |
| MACD: Buy Signal | May 18, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
Newest 20 of 125.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 304.67 +22.0% upside
Now 249.66
- Target (low)
- 261.81
- Target (mean)
- 304.67
- Target (high)
- 343.27
Ratings (0m) 22 21 buy · 1 hold · 0 sell
- Strong buy5
- Buy16
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 22
- 1 month ago 20
- 2 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.12 | 0.65 – 1.65 | 0.00 | 0.0% | 367.14M | +71.9% | 4 |
| Next quarter | 1.42 | 0.60 – 2.23 | 0.00 | 0.0% | 414.65M | +67.5% | 4 |
| Current year | 10.08 | 3.61 – 15.62 | 0.00 | 0.0% | 1.37B | +90.8% | 5 |
| Next year | 8.90 | 6.26 – 12.56 | 10.08 | -11.7% | 2.01B | +46.2% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 25, 2026 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 15, 2026 | Raymond James | Downgrade | Strong Buy | Outperform |
| Sep 2, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 1, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 1, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 31, 2026 | B of A Securities | Maintained | Buy | Buy |
| Aug 31, 2026 | Jefferies | Maintained | Buy | Buy |
| Aug 31, 2026 | Stifel | Maintained | Buy | Buy |
| Aug 31, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 27, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 19, 2026 | BMO Capital | Initiated | — | Outperform |
| Aug 14, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 14, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 23, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 19, 2026 | Citigroup | Initiated | — | Buy |
| May 15, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 11, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 8, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Apr 16, 2026 | B of A Securities | Maintained | Buy | Buy |
| Apr 9, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Mar 3, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Feb 12, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jan 30, 2026 | B of A Securities | Maintained | Buy | Buy |
| Jan 28, 2026 | Barclays | Initiated | — | Overweight |
| Jan 20, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jan 20, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
